NGM Biopharmaceuticals Articles
NGM Biopharma in deal with Janssen for novel diabetes therapeutics; Microbiotix in-licenses drugs from Merck & Co
4 January 2013
Showing 1-2 of 2 articles
- 1
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
